Invex Receives UK Approval to Commence Phase III Trial
Filed with ASX · · 3 pages · English
Invex Therapeutics Ltd(Invex,ASX:IXC,ortheCompany) a clinical-stage biopharmaceutical company focused on the development and commercialisation of Presendin™ (sustained release Exenatide) for neurological conditions relating to raised intracranial pressure, today announces the Medicines and Healthcare products Regulatory Agency (MHRA) has approved the Company’s Clinical Trial Authorisation (CTA) to
Invex Therapeutics Ltd. on 6ix
Story so far
Earlier from Invex Therapeutics
- Half Yearly Report and Accounts
- New Executive Director and Chairman Agreements
- Appointment IIH EVOLVE Phase III Trial Steering Group Chair
- Invex Therapeutics: Chairman's Address to Shareholders at AGM
- Global Phase 3 Trial of Presendin to Launch in Q4 2021
Later from Invex Therapeutics
- HREC and TGA Approval to Commence Phase 3 in Australia
- Quarterly Activities/Appendix 4C Cash Flow Report
- Invex receives IND approval
- 4E and Annual Report to shareholders
- Second HREC Approval for IIH EVOLVE Phase III Clinical Trial
Follow Invex Therapeutics into a list and get an email when it puts out news.
Follow Invex Therapeutics